Raymond James & Associates Aldeyra Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 34,884 shares of ALDX stock, worth $175,466. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,884
Previous 34,633 0.72%
Holding current value
$175,466
Previous $114,000 64.91%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$3.19 - $6.32 $800 - $1,586
251 Added 0.72%
34,884 $188,000
Q2 2024

Jul 19, 2024
SELL
$3.25 - $4.72 $4,520 - $6,565
-1,391 Reduced 3.86%
34,633 $114,000
Q1 2024

Apr 22, 2024
BUY
$2.77 - $4.22 $8,974 - $13,672
3,240 Added 9.88%
36,024 $117,000
Q4 2023

Jan 16, 2024
SELL
$1.47 - $6.06 $26,852 - $110,698
-18,267 Reduced 35.78%
32,784 $115,000
Q3 2023

Oct 24, 2023
SELL
$6.11 - $8.16 $4,649 - $6,209
-761 Reduced 1.47%
51,051 $341,000
Q2 2023

Jul 25, 2023
BUY
$7.11 - $11.89 $177,536 - $296,893
24,970 Added 93.03%
51,812 $434,000
Q1 2023

Apr 14, 2023
BUY
$5.77 - $9.93 $6,768 - $11,647
1,173 Added 4.57%
26,842 $266,000
Q4 2022

Feb 08, 2023
SELL
$5.08 - $7.09 $7,010 - $9,784
-1,380 Reduced 5.1%
25,669 $178,000
Q3 2022

Oct 25, 2022
SELL
$3.8 - $7.74 $15,872 - $32,329
-4,177 Reduced 13.38%
27,049 $144,000
Q2 2022

Aug 12, 2022
BUY
$2.43 - $4.85 $11,955 - $23,862
4,920 Added 18.7%
31,226 $125,000
Q1 2022

May 11, 2022
BUY
$3.25 - $5.17 $14,979 - $23,828
4,609 Added 21.24%
26,306 $117,000
Q4 2021

Feb 08, 2022
SELL
$3.5 - $9.63 $84,525 - $232,564
-24,150 Reduced 52.68%
21,697 $87,000
Q3 2021

Nov 02, 2021
SELL
$7.94 - $11.31 $3,930 - $5,598
-495 Reduced 1.07%
45,847 $403,000
Q2 2021

Aug 11, 2021
BUY
$10.44 - $14.85 $250,998 - $357,023
24,042 Added 107.81%
46,342 $525,000
Q1 2021

May 14, 2021
SELL
$6.53 - $14.42 $3,251 - $7,181
-498 Reduced 2.18%
22,300 $265,000
Q3 2020

Nov 04, 2020
BUY
$4.0 - $7.53 $2,792 - $5,255
698 Added 3.16%
22,798 $169,000
Q2 2020

Jul 28, 2020
SELL
$1.97 - $5.05 $4,925 - $12,625
-2,500 Reduced 10.16%
22,100 $92,000
Q1 2020

Apr 21, 2020
BUY
$1.62 - $6.4 $3,240 - $12,800
2,000 Added 8.85%
24,600 $61,000
Q4 2019

Feb 12, 2020
BUY
$4.73 - $7.98 $1,892 - $3,192
400 Added 1.8%
22,600 $131,000
Q3 2019

Nov 07, 2019
BUY
$4.41 - $6.12 $22,491 - $31,212
5,100 Added 29.82%
22,200 $117,000
Q2 2019

Aug 06, 2019
BUY
$6.0 - $9.0 $102,600 - $153,900
17,100 New
17,100 $103,000

Others Institutions Holding ALDX

# of Institutions
117
Shares Held
36.2M
Call Options Held
196K
Put Options Held
142K
View Full List

About Aldeyra Therapeutics, Inc.

ALDX Quotes by TradingView
  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $293M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email